Philip A Starr

Aug 19, 2024 | inkl.com | Philip A Starr

PA ArchiveA brain implant can help people with Parkinson’s disease deal with movement problems during the day and insomnia at night, new research suggests. The study found that the device, which is controlled by brain activity, could provide personalised continual and improved treatment for the symptoms in some people with the condition. When the implant detects changes in symptoms from brain activity, it releases pulses of electricity.

May 9, 2024 | nature.com | Zixiao Yin |Philip A Starr |Simon Little

AbstractSleep disturbances profoundly affect the quality of life in individuals with neurological disorders. Closed-loop deep brain stimulation (DBS) holds promise for alleviating sleep symptoms, however, this technique necessitates automated sleep stage decoding from intracranial signals.

Apr 21, 2024 | nature.com | Jeffrey A. Herron |Gregory Worrell |Philip A Starr

Neuromodulation and brain–computer interfaces are rapidly evolving fields with distinct origins but with the shared goal of improving the lives of people with neurological and psychiatric disorders or injuries. Their increasing technological overlap provides new opportunities for collaborative work and rapid progress in neurotechnology.

Feb 26, 2024 | nature.com | Fahim Anjum |Philip A Starr |Derk Jan Dijk

AbstractSleep disturbance is a prevalent and disabling comorbidity in Parkinson’s disease (PD). We performed multi-night (n = 57) at-home intracranial recordings from electrocorticography and subcortical electrodes using sensing-enabled Deep Brain Stimulation (DBS), paired with portable polysomnography in four PD participants and one with cervical dystonia (clinical trial: NCT03582891). Cortico-basal activity in delta increased and in beta decreased during NREM (N2 + N3) versus wakefulness in PD.

Feb 6, 2024 | biologicalpsychiatryjournal.com | Prasad Shirvalkar |Philip A Starr |Edward F. Chang

Chronic pain affects 1 in 4 adults and is often refractory to treatment. Deep brain stimulation (DBS) for pain has been studied for over 70 years, but an objective biomarker that can guide therapy is still lacking. Previous research was limited by focusing on experimental pain tasks in healthy individuals, constraining clinical application. This study aimed to identify real-world brain biomarkers of chronic pain to personalize DBS.